Alerts will be sent to your verified email
Verify Email
WANBURY
|
Wanbury
|
Jagsonpal Pharma
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-68.24 % | 11.8 % | 26.14 % |
|
5yr average Equity Multiplier
|
-5.8 | 1.31 | 2.82 |
|
5yr Average Asset Turnover Ratio
|
1.45 | 1.18 | 1.1 |
|
5yr Avg Net Profit Margin
|
4.37 % | 7.67 % | 9.03 % |
|
Price to Book
|
0.0 | 5.24 | 8.1 |
|
P/E
|
19.78 | 36.24 | 37.6 |
|
5yr Avg Cash Conversion Cycle
|
-125.27 Days | -6.79 Days | -18.02 Days |
|
Inventory Days
|
19.82 Days | 60.26 Days | 77.22 Days |
|
Days Receivable
|
46.87 Days | 25.87 Days | 81.36 Days |
|
Days Payable
|
189.66 Days | 67.96 Days | 175.58 Days |
|
5yr Average Interest Coverage Ratio
|
1.85 | 51.15 | 10.3 |
|
5yr Avg ROCE
|
-65.2 % | 15.71 % | 33.27 % |
|
5yr Avg Operating Profit Margin
|
6.05 % | 11.17 % | 17.37 % |
|
5 yr average Debt to Equity
|
-1.62 | 0.03 | 0.73 |
|
5yr CAGR Net Profit
|
-15.99 % | 29.92 % | 29.43 % |
|
5yr Average Return on Assets
|
6.04 % | 9.04 % | 10.17 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
39.79 % | 68.09 % | 72.51 % |
|
Share Pledged by Promoters
|
71.05 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-12.3 % | -2.25 % | 6.76 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -6.16 % |
|
Wanbury
|
Jagsonpal Pharma
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
